Co-Authors
This is a "connection" page, showing publications co-authored by James Crowe and Robert Carnahan.
Connection Strength
1.209
-
Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals. Cell Rep. 2021 08 24; 36(8):109604.
Score: 0.240
-
Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell. 2021 04 29; 184(9):2316-2331.e15.
Score: 0.234
-
Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020 08; 584(7821):443-449.
Score: 0.223
-
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med. 2020 09; 26(9):1422-1427.
Score: 0.223
-
Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell Rep Med. 2021 06 15; 2(6):100313.
Score: 0.059
-
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell. 2021 04 01; 184(7):1804-1820.e16.
Score: 0.058
-
Comparison of Subgenomic and Total RNA in SARS-CoV-2 Challenged Rhesus Macaques. J Virol. 2021 Jan 20.
Score: 0.058
-
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. Cell Host Microbe. 2021 01 13; 29(1):44-57.e9.
Score: 0.057
-
Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat Immunol. 2020 12; 21(12):1506-1516.
Score: 0.057